FDA says contract lab Sure-Biochem missed Burkholderia cepacia in drug samples and cites broad CGMP failures.
What happened
FDA inspected the Sure-Biochem contract testing laboratory in Camden, NJ, from September 28 to October 7, 2022, and reviewed its October 27, 2022 response to the inspection findings (Form FDA 483). Investigators found the lab released a lot of Salmonella test media that its own procedure said should have been rejected, and used unvalidated microbial test methods that reported "Not Detected" for Burkholderia cepacia complex in pre- and post-surgical oral care drug products, which another laboratory later found contained Burkholderia contaminans. FDA also found the quality unit was not controlling testing operations and that laboratory records were incomplete.
What FDA found
The lab's growth promotion testing of microbiological media was not properly set up or followed: it accepted a Salmonella media lot even though E. coli grew in it when the lab's own procedure said that growth should be stopped, and it did not run growth promotion testing on every lot of media received.
21 CFR 211.160(a) and 211.160(b)The lab's alternative microbial test methods were never shown to reliably detect objectionable organisms, and one such method reported "Not Detected" for Burkholderia cepacia complex in drugs for patients who are especially prone to infection.
21 CFR 211.160(b)The quality unit lacked adequate control: it did not keep documentation showing that buffers, reagents and media were reviewed and met specifications before use, did not make sure its own written procedures were followed, and did not have an adequate CGMP training program.
21 CFR 211.22(a) and 211.22(d)Laboratory records did not include complete data, such as the test methods used, the results and how they compared with specifications, the critical equipment used, and raw data backing the alternative methods.
21 CFR 211.194(a)
What FDA wants
FDA tells the firm to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, including independent assessments, a retrospective review of prior testing, and notification of clients who received incorrect results. If corrective actions cannot be finished in that time, the firm must state why and give a completion schedule.
Who should pay attention
- drug manufacturers that send products to this lab for microbial testing
- brands selling pre- and post-surgical oral care drug products
- quality teams that rely on contract lab certificates of analysis
This is a summary. Read the original letter on fda.gov.